BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 20215640)

  • 1. Pim2 cooperates with PML-RARalpha to induce acute myeloid leukemia in a bone marrow transplantation model.
    Agrawal-Singh S; Koschmieder S; Gelsing S; Stocking C; Stehling M; Thiede C; Thoennissen NH; Köhler G; Valk PJ; Delwel R; Mills K; Bäumer N; Tickenbrock L; Hansen K; Berdel WE; Müller-Tidow C; Serve H
    Blood; 2010 Jun; 115(22):4507-16. PubMed ID: 20215640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model.
    Kelly LM; Kutok JL; Williams IR; Boulton CL; Amaral SM; Curley DP; Ley TJ; Gilliland DG
    Proc Natl Acad Sci U S A; 2002 Jun; 99(12):8283-8. PubMed ID: 12060771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment-influenced associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia.
    Gallagher RE; Moser BK; Racevskis J; Poiré X; Bloomfield CD; Carroll AJ; Ketterling RP; Roulston D; Schachter-Tokarz E; Zhou DC; Chen IM; Harvey R; Koval G; Sher DA; Feusner JH; Tallman MS; Larson RA; Powell BL; Appelbaum FR; Paietta E; Willman CL; Stock W
    Blood; 2012 Sep; 120(10):2098-108. PubMed ID: 22734072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of B94 (TNFAIP2) as a potential retinoic acid target gene in acute promyelocytic leukemia.
    Rusiniak ME; Yu M; Ross DT; Tolhurst EC; Slack JL
    Cancer Res; 2000 Apr; 60(7):1824-9. PubMed ID: 10766166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657.
    Sohal J; Phan VT; Chan PV; Davis EM; Patel B; Kelly LM; Abrams TJ; O'Farrell AM; Gilliland DG; Le Beau MM; Kogan SC
    Blood; 2003 Apr; 101(8):3188-97. PubMed ID: 12515727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF-RARalpha and NPM-RARalpha.
    Cheng GX; Zhu XH; Men XQ; Wang L; Huang QH; Jin XL; Xiong SM; Zhu J; Guo WM; Chen JQ; Xu SF; So E; Chan LC; Waxman S; Zelent A; Chen GQ; Dong S; Liu JX; Chen SJ
    Proc Natl Acad Sci U S A; 1999 May; 96(11):6318-23. PubMed ID: 10339585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Asynchronous expression of myeloid antigens in leukemic cells in a PML/RARalpha transgenic mouse model.
    Santana BA; Pintão MC; Abreu e Lima RS; Scheucher PS; Santos GA; Garcia AB; Falcão RP; Rego EM
    Braz J Med Biol Res; 2006 May; 39(5):615-20. PubMed ID: 16648899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of
    Zhang F; Zhu YL; Deng WL; Zhu J; Zhang J
    J Leukoc Biol; 2017 Mar; 101(3):655-664. PubMed ID: 27605212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TRIB3 Promotes APL Progression through Stabilization of the Oncoprotein PML-RARα and Inhibition of p53-Mediated Senescence.
    Li K; Wang F; Cao WB; Lv XX; Hua F; Cui B; Yu JJ; Zhang XW; Shang S; Liu SS; Yu JM; Han MZ; Huang B; Zhang TT; Li X; Jiang JD; Hu ZW
    Cancer Cell; 2017 May; 31(5):697-710.e7. PubMed ID: 28486108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquired, nonrandom chromosomal abnormalities associated with the development of acute promyelocytic leukemia in transgenic mice.
    Zimonjic DB; Pollock JL; Westervelt P; Popescu NC; Ley TJ
    Proc Natl Acad Sci U S A; 2000 Nov; 97(24):13306-11. PubMed ID: 11087871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PML-RARα interferes with erythropoiesis by repressing LMO2 in acute promyelocytic leukaemia.
    Yang X; Tan Y; Wang P; Zhang H; Zhao M; Zhao X; Wang K
    J Cell Mol Med; 2018 Dec; 22(12):6275-6284. PubMed ID: 30320491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PML/RARα-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia.
    Bräuer-Hartmann D; Hartmann JU; Wurm AA; Gerloff D; Katzerke C; Verga Falzacappa MV; Pelicci PG; Müller-Tidow C; Tenen DG; Niederwieser D; Behre G
    Cancer Res; 2015 Aug; 75(16):3411-24. PubMed ID: 26041820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice.
    He LZ; Tribioli C; Rivi R; Peruzzi D; Pelicci PG; Soares V; Cattoretti G; Pandolfi PP
    Proc Natl Acad Sci U S A; 1997 May; 94(10):5302-7. PubMed ID: 9144232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins.
    Rego EM; He LZ; Warrell RP; Wang ZG; Pandolfi PP
    Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10173-8. PubMed ID: 10954752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells.
    Zheng X; Seshire A; Rüster B; Bug G; Beissert T; Puccetti E; Hoelzer D; Henschler R; Ruthardt M
    Haematologica; 2007 Mar; 92(3):323-31. PubMed ID: 17339181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia.
    Hospital MA; Jacquel A; Mazed F; Saland E; Larrue C; Mondesir J; Birsen R; Green AS; Lambert M; Sujobert P; Gautier EF; Salnot V; Le Gall M; Decroocq J; Poulain L; Jacque N; Fontenay M; Kosmider O; Récher C; Auberger P; Mayeux P; Bouscary D; Sarry JE; Tamburini J
    Leukemia; 2018 Mar; 32(3):597-605. PubMed ID: 28914261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-penetrance mouse model of acute promyelocytic leukemia with very low levels of PML-RARalpha expression.
    Westervelt P; Lane AA; Pollock JL; Oldfather K; Holt MS; Zimonjic DB; Popescu NC; DiPersio JF; Ley TJ
    Blood; 2003 Sep; 102(5):1857-65. PubMed ID: 12750176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the molecular pathogenesis of acute promyelocytic leukemia.
    Lo-Coco F; Hasan SK
    Best Pract Res Clin Haematol; 2014 Mar; 27(1):3-9. PubMed ID: 24907012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy.
    Cicconi L; Divona M; Ciardi C; Ottone T; Ferrantini A; Lavorgna S; Alfonso V; Paoloni F; Piciocchi A; Avvisati G; Ferrara F; Di Bona E; Albano F; Breccia M; Cerqui E; Sborgia M; Kropp MG; Santoro A; Levis A; Sica S; Amadori S; Voso MT; Mandelli F; Lo-Coco F
    Leukemia; 2016 Oct; 30(10):1987-1992. PubMed ID: 27133819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low HOX gene expression in PML-RARα-positive leukemia results from suppressed histone demethylation.
    Rejlova K; Musilova A; Kramarzova KS; Zaliova M; Fiser K; Alberich-Jorda M; Trka J; Starkova J
    Epigenetics; 2018; 13(1):73-84. PubMed ID: 29224413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.